Tag: Kidney cancer

Sorafenib, a multikinase inhibitor also known by the brand name Nexavar®, was one of the first targeted therapies to demonstrate a significant survival benefit in patients with advanced hepatocellular carcinoma. This oral medication is primarily used to treat three distinct types of advanced cancer: liver, kidney, and a specific type of thyroid carcinoma.

Pazopanib, marketed under the brand name Votrient, has demonstrated significant efficacy in treating specific types of advanced cancers. Approved by the U.S. Food and Drug Administration (FDA) for both advanced renal cell carcinoma and advanced soft tissue sarcoma, this medication is a powerful component of targeted therapy regimens.